COSTA MESA, Calif.--(BUSINESS WIRE)--Feb. 17, 2006--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that, subject to availability of future funding, it expects to initiate its Oxycyte(TM) Phase II sickle cell anemia trial in the second quarter of 2006. Trial initiation has been delayed based on the Company's receipt of a letter from the U.S. Food and Drug Administration (FDA) placing the trial on clinical hold for protocol revisions. Synthetic Blood intends to actively and diligently work with FDA officials to satisfy the necessary requirements.
